The new company hopes to turn recombinant adeno-associated virus-based gene editing, which has minimal off-target effects, into new therapies.
NEW YORK (GenomeWeb News) – Pacific Biosciences has filed a prospectus for the resale of up to 5.5 million shares of its stock, issuable upon the exercise of warrants.
NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday that its fourth-quarter revenues fell 52 percent year over year but were up sequentially as product revenue jumped from the third quarter.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.